Abbott study links CGM use in type 2 diabetes patients on basal insulin to 45% lower 12-month mortality risk

Abbott said new real-world data also linked Libre use to fewer hospitalizations for acute diabetes events, with additional FreeDM2 trial analyses to be presented at EASD starting Sept. 28, 2026.